Label: Information for the User
Openvas Plus 40 mg/25 mg Film-Coated Tablets
Olmesartan medoxomil/Hydrochlorothiazide
Read this label carefully before starting to take this medicine, because it contains important information for you.
-Keep this label, as you may need to read it again.
-If you have any questions, consult your doctor or pharmacist.
-This medicine has been prescribed only for you, and you should not give it to others, even if they have the same symptoms as you, as it may harm them.
-If you experience any adverse effects, consult your doctor or pharmacist, even if they are not listed in this label. See section 4.
Openvas Plus contains two active ingredients, olmesartan medoxomil and hydrochlorothiazide, which are used in the treatment of high blood pressure (hypertension):
Openvas Plus will only be given if treatment with Openvas (olmesartan medoxomil) alone has not adequately controlled your blood pressure. The concurrent administration of both active ingredients in Openvas Plus contributes to reducing blood pressure more than if each active ingredient were administered alone.
You may already be taking medications to treat high blood pressure, but your doctor may believe it necessary for you to take Openvas Plus to lower it further.
High blood pressure can be controlled with medications like Openvas Plus tablets. Your doctor may also have recommended that you make some lifestyle changes to help lower your blood pressure (for example, losing weight, quitting smoking, reducing alcohol consumption, and reducing the amount of salt in your diet). Your doctor may also have recommended that you engage in regular exercise, such as walking or swimming. It is essential to follow your doctor's advice.
Do not take Openvas Plus
If you think you have any of these cases, or are unsure, do not take the tablets. Talk to your doctor and follow their advice.
Warnings and precautions
Consult your doctor before starting to take Openvas Plus.
Before taking the tablets, tell your doctor if you are taking any of the following medications used to treat high blood pressure (hypertension):
Your doctor may monitor your kidney function, blood pressure, and electrolyte levels in the blood (for example, potassium) at regular intervals.
See also the information under the heading “Do not take Openvas Plus”
Before taking the tablets,tell your doctorif you have any of the following health problems:
Contact your doctor if you experience any of the following symptoms:
Your doctor may want to see you more often and perform some tests if you have any of these problems.
Openvas Plus may cause an increase in blood levels of fats and uric acid (which causes gout - painful swelling of the joints). Your doctor will probably want to perform blood tests from time to time to monitor these possible changes.
There may be a change in blood levels of certain chemical substances called electrolytes. Your doctor will probably want to perform blood tests from time to time to monitor this possible change. Some signs of electrolyte changes are: thirst, dry mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling weak, slow, tired, drowsy, or restless, nausea, vomiting, decreased need to urinate, rapid heart rate.Tell your doctor if you notice any of these symptoms.
Like any other medication that lowers blood pressure, excessive lowering of blood pressure in patients with heart or brain blood flow problems can cause a heart attack or stroke. Therefore, your doctor will carefully monitor your blood pressure.
If you are to undergo parathyroid function tests, stop taking Openvas Plus before the tests are performed.
It is reported to athletes that this medication contains a component that may establish a positive analytical result for doping control.
Inform your doctor if you are pregnant or think you may be pregnant. Openvas Plus is not recommended for use at the beginning of pregnancy, and it should not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken during this period (see Pregnancy section).
Children and adolescents
Openvas Plus is not recommended for children and adolescents under 18 years old.
Use of Openvas Plus with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Particularly, inform your doctor or pharmacist about any of the following medications:
Your doctor may need to modify your dose and/or take other precautions:
If you are taking an angiotensin-converting enzyme inhibitor (ACE inhibitor) or aliskiren (see also the information under the headings “Do not take Openvas Plus” and “Warnings and precautions”).
-Potassium supplements (as well as salt substitutes that contain potassium).
-Medications that increase urine elimination (diuretics).
-Heparin (to thin the blood).
-Laxatives.
-Glucocorticoids.
-Adrenocorticotropic hormone (ACTH).
-Carbenoxolone (medication for the treatment of mouth and stomach ulcers).
-Penicillin G sodium (antibiotic also called benzylpenicillin sodium).
-Some analgesics such as aspirin or salicylates.
Taking Openvas Plus with food and drinks
Openvas Plus can be taken with or without food.
Be careful when drinking alcohol while taking Openvas Plus, as some people may feel weak or dizzy. If this happens, do not drink any alcohol, including wine, beer, or alcoholic beverages.
Black patients
Like other similar medications, the blood pressure-lowering effect of Openvas Plus is somewhat less in black patients.
Pregnancy and breastfeeding
Pregnancy
Inform your doctor if you are pregnant or think you may be pregnant. Your doctor will advise you to stop taking Openvas Plus before becoming pregnant or as soon as you know you are pregnant, and will advise you to take another medication instead of Openvas Plus. Openvas Plus is not recommended for use during pregnancy, and it should not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken during this period.
Breastfeeding
Inform your doctor if you are breastfeeding or planning to start breastfeeding. Openvas Plus is not recommended for breastfeeding mothers, and your doctor may choose another treatment if you want to breastfeed.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Use in athletes
It is reported to athletes that this medication contains a component (hydrochlorothiazide) that may establish a positive analytical result for doping control.
Driving and operating machines
You may feel drowsy or dizzy while taking Openvas Plus for high blood pressure. If this happens, do not drive or operate machines until the symptoms have disappeared. Consult your doctor.
Openvas Plus contains lactose
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow exactly the administration instructions for this medication as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
The recommended doseis 1 Openvas Plus 40 mg/12.5 mg tablet per day. If blood pressure is not adequately controlled, your doctor may change the dose to 1 Openvas Plus 40 mg/25 mg tablet per day.
Take the tablets with water. If possible, take your doseat the same time every day, for example, at breakfast time. It is essential to continue taking Openvas Plus until your doctor tells you to stop.
If you take more Openvas Plus than you should
If you take more tablets than you should take or if a child accidentally ingests one or more tablets, contact your doctor immediately or go to the nearest hospital emergency department and bring the medication packaging with you.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Openvas Plus
If you forget to take a dose, take the usual dose the next day.Do nottake a double dose to compensate for the missed doses.
If you interrupt treatment with Openvas Plus
It is essential to continue taking Openvas Plus, unless your doctor tells you to stop.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
However, the following side effects can be serious:
Openvas Plus is a combination of two active principles. The following information, first, describes the side effects reported so far with the combination Openvas Plus (in addition to those already mentioned) and, second, the known side effects of the two active principles separately.
These are other side effects known so far with Openvas Plus:
If these effects occur, they are often mild anddo not need to interrupt treatment.
Frequent side effects (can affect up to 1 in 10 people):
Dizziness, weakness, headache, fatigue, chest pain, swelling of ankles, feet, legs, hands, or arms.
Rare side effects (can affect up to 1 in 100 people):
Fast and intense heartbeat (palpitations), hives, eczema, dizziness, cough, indigestion, abdominal pain, nausea, vomiting, diarrhea, muscle cramps, and muscle pain, joint pain, arm and leg pain, back pain, erectile dysfunction in men, blood in urine.
Infrequently, some changes in blood tests have also been observed that include:
Increased levels of blood fat, increased urea or uric acid in blood, increased creatinine, increased or decreased levels of potassium in blood, increased levels of calcium in blood, increased blood sugar, increased values of liver function tests. Your doctor will monitor you through a blood test and tell you if you need to take any measures.
Rare side effects (can affect up to 1 in 1,000 people):
Unpleasant sensation, alterations in consciousness, skin swelling (hives), acute renal insufficiency.
Infrequently, some changes in blood test results have also been observed that include: increased urea nitrogen in blood, decreased values of hemoglobin and hematocrit. Your doctor will monitor you through a blood test and tell you if you need to take any measures.
Additional side effects reported with the use of olmesartan medoxomil or hydrochlorothiazide alone, but not with Openvas Plus or in a higher frequency:
Olmesartan medoxomil:
Frequent side effects (can affect up to 1 in 10 people):
Bronchitis, cough, congestion, and nasal secretion, sore throat, abdominal pain, indigestion, diarrhea, nausea, gastroenteritis, joint or bone pain, back pain, blood in urine, urinary tract infection, flu-like symptoms, pain.
Infrequently, some changes in blood test results have also been observed that include: increased levels of blood fat, increased urea or uric acid in blood, increased levels of liver or muscle function.
Rare side effects (can affect up to 1 in 100 people):
Fast and intense allergic reactions that can affect the entire body and can cause breathing problems, as well as a rapid decrease in blood pressure that can even lead to fainting (anaphylactic reactions), inflammation of the face, angina (chest pain or discomfort, known as angina pectoris), unpleasant sensation, skin rash, itching, exanthema (skin rash), skin swelling (hives).
Infrequently, some changes in blood test results have also been observed that include: reduction in the number of a type of blood cell, called platelets (thrombocytopenia).
Rare side effects (can affect up to 1 in 1,000 people):
Renal function deterioration, lack of energy.
Infrequently, some changes in blood test results have also been observed that include: increased potassium in blood.
Hydrochlorothiazide:
Very frequent side effects (can affect more than 1 in 10 people):
Changes in blood tests that include: increased blood fat and uric acid levels.
Frequent side effects (can affect up to 1 in 10 people):
Confusion, abdominal pain, stomach discomfort, feeling of swelling, diarrhea, nausea, vomiting, constipation, glucose excretion in urine.
Infrequently, some changes in blood test results have also been observed that include: increased creatinine, urea, calcium, and sugar levels in blood, decreased levels of chloride, potassium, magnesium, and sodium in blood. Increased serum amylase (hyperamylasemia).
Rare side effects (can affect up to 1 in 100 people):
Loss of appetite, severe difficulty breathing,allergic skin reactions (hypersensitivity reactions), worsening of pre-existing myopia, erythema, light sensitivity skin reactions, itching, purple spots on the skin due to small hemorrhages (purpura), skin swelling (hives).
Rare side effects (can affect up to 1 in 1,000 people):
Salivary gland inflammation and pain, decreased white blood cell count, decreased platelet count in blood, anemia, bone marrow depression, restlessness, depression, sleep problems, feeling of loss of interest (apathy), tingling and numbness, seizures, yellow vision, blurred vision, dry eyes, irregular heartbeat, inflammation of blood vessels, blood clots (thrombosis or embolism), lung inflammation, fluid accumulation in lungs, pancreatitis, jaundice, gallbladder infection, symptoms of lupus erythematosus (such as skin rash, joint pain, and cold hands and fingers), skin allergic reactions, skin peeling and blistering, non-infectious kidney inflammation (interstitial nephritis), fever, muscle weakness(which sometimes causes movement alteration).
Very rare side effects (can affect up to 1 in 10,000 people):
Electrolyte imbalance that can cause an abnormally low level of chloride in blood (hypochloremic alkalosis), intestinal obstruction (paralytic ileus).
Acute respiratory distress (symptoms include severe difficulty breathing, fever, weakness, and confusion).
Unknown side effects (frequency cannot be estimated from available data):
Decreased vision or eye pain (possible signs of fluid accumulation in the vascular layer of the eye (choroidal hemorrhage) or acute angle-closure glaucoma).
Skin cancer and lip cancer (non-melanoma skin cancer).
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration date appearing on the packaging and blister (after “CAD.”).The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Composition of Openvas Plus
The active principles are:
Openvas Plus 40 mg/25 mg: each film-coated tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
The other components are:microcrystalline cellulose, lactose monohydrate*, hypromellose low-substitution, hypromellose, magnesium stearate, titanium dioxide (E171), talc, and iron(III) oxide (E172).
* See previous section“Openvas Plus contains lactose”
Appearance of the product and contents of the packaging
Openvas Plus 40 mg/25 mg film-coated tablets are pink, oval-shaped, 15 x 7 mm tablets with the inscription “C25” on one face.
Openvas Plus film-coated tablets are available in packaging of 14, 28, 30, 56, 84, 90, 98, 10 x 28, and 10 x 30 tablets, and in packaging with pre-cut single-dose blisters of 10, 50, and 500 tablets.
Not all packaging is marketed.
Marketing authorization holder:
Daiichi Sankyo España, S.A.
Paseo del Club Deportivo nº1,
Ground floor left
28223 Pozuelo de Alarcón - Madrid
Responsible for manufacturing:
Daiichi Sankyo Europe GmbH
Luitpoldstrasse 1
85276 Pfaffenhofen
Germany
or
Berlin-Chemie AG
Glienicker Weg 125, D-12489 Berlin
Germany
or
Menarini – Von Heyden GmbH
Leipziger Strasse 7-13
01097 Dresden
Germany
This medicine is authorized in the member states of the European Economic Area with the following names:
Germany: Olmes Plus
Italy: Plaunazide
Spain: Openvas Plus
Last review date of this leaflet: March 2022
Other sources of information
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.